# EDGAR Filing Document

**Accession Number:** 0000073290
**File Stem:** 0001513162-23-000029
**Filing Date:** 2023-3
**Character Count:** 3489
**Document Hash:** 47154b4b0984f06e0af1a77ee1cdd1d8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001513162-23-000029.hdr.sgml**: 20230302

**ACCESSION NUMBER**: 0001513162-23-000029

**CONFORMED SUBMISSION TYPE**: 424B5

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230302

**DATE AS OF CHANGE**: 20230302

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOMERICA INC
- **CENTRAL INDEX KEY:** 0000073290
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **IRS NUMBER:** 952645573
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0531

**FILING VALUES:**
- **FORM TYPE:** 424B5
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-239980
- **FILM NUMBER:** 23700019

**BUSINESS ADDRESS:**
- **STREET 1:** 17571 VON KARMAN AVENUE
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614
- **BUSINESS PHONE:** 9496452111

**MAIL ADDRESS:**
- **STREET 1:** 17571 VON KARMAN AVENUE
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NMS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19871130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NUCLEAR MEDICAL SYSTEMS INC
- **DATE OF NAME CHANGE:** 19830216

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NUCLEAR INSTRUMENTS INC
- **DATE OF NAME CHANGE:** 19720508

**Filed Pursuant to Rule 424(b)(5)<br>Registration No. 333-239980**

**SUPPLEMENT TO PROSPECTUS SUPPLEMENT DATED JANUARY 22, 2021** 

(To Prospectus dated September 30, 2020)

![](bmra_logo.jpg)

**BIOMERICA, INC.**

This supplement to prospectus supplement (this "Supplement") supplements and amends the prospectus supplement dated January 22, 2021 (the "Prospectus Supplement"). This Supplement should be read in conjunction with the Prospectus Supplement and the Prospectus dated September 30, 2020. This Supplement is qualified by reference to the Prospectus Supplement, except to the extent that the information presented herein supersedes the information contained in the Prospectus Supplement.

On December 1, 2017, we entered into an At Market Issuance Sales Agreement with B. Riley Securities ("Sales Agent"), which agreement was subsequently amended on January 22, 2021 pursuant to an Amendment No. 1 to At Market Sales Agreement (such agreement, as amended, the "Sales Agreement"), in connection with our "at-the-market" sales program relating to the issuance and sale of shares of our common stock under the Prospectus Supplement. In accordance with the terms of the Sales Agreement, we could offer and sell shares of our common stock having an aggregate gross sale price of up to $15,000,000 from time to time through the Sales Agent pursuant to "at-the-market" transactions. As of the date of this Supplement, we have sold an aggregate of approximately $2,014,054 of shares of our common stock pursuant to the Sales Agreement.

The purpose of this Supplement is to terminate the continuous offering of shares of our common stock under the Prospectus Supplement and suspend our "at-the-market" sales program pursuant to the Sales Agreement, effective as of March 2, 2023. Accordingly, following the filing of this Supplement, we will not make any further sales of our common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the Securities and Exchange Commission. For the avoidance of doubt, we note that the Sales Agreement will remain in full force and effect following the filing of this Supplement.

The date of this supplement to prospectus supplement is March 2, 2023.